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MENSTRUAL CYCLE WORSENING OF EPILEPTIC
SEIZURES IN WOMEN WITH SYMPTOMATIC
FOCAL EPILEPSY 
Ana Carolina Belini Bazán, Maria Augusta Montenegro,
Fernando Cendes, Li Li Min, Carlos A.M. Guerreiro
A B S T R A C T- I n t ro d u c t i o n : H o rmonal fluctuation is responsible for worsening of epileptic seizures during
the menstrual cycle. Objective: To identify irregularities in the menstrual cycles of women with mesial
temporal lobe epilepsy (MTLE) and extratemporal focal epilepsy (ETFE) and correlate the frequency of sei-
z u res during the menstrual cycles. Method: We evaluated prospectively women in the menacme with M T L E
and ETFE. Calendars were provided for these patients, and they were asked to mark their seizure fre q u e ncy
a c c o rding to the menses. Calendars were reviewed in each routine medical appointment. Results: T h i rt y -
nine patients with MTLE and 14 with ETFE were evaluated. We re g i s t e red 211 cycles in the patients with
MTLE and 49 in those with ETFE. Irregular menstrual cycles were found in 28 (28/39, 71.7%) patients with
MTLE and 6 (6/14, 42.8%) with ETFE (p=0.052). Pre m e n s t rual seizure worsening was observed in 46 (21.8%)
patients with MTLE and 9 (18.3%) with ETFE (p=0.596). Menstrual worsening was observed in 47 (22.2%)
patients with MTLE and 15 (30.6%) with ETFE (p=0. 217). Ovulatory worsening was observed in 36 (17%)
patients with MTLE and 13 (26.5%) with ETFE (p=0,126). Catamenial worsening was observed in 58 (27.4%)
of the patients with MTLE and in 17 (34.7%) of the patients with ETFE (p=0.315). Conclusion: T h e re was
no diff e rence between the group of patients with MTLE and ETFE re g a rding the frequency of irregular cy-
cles and seizure worsening during the premenstrual, menstrual, catamenial or ovulatory periods. 
KEY WORDS: epilepsy, catamenial, temporal lobe epilepsy, extra-temporal epilepsy, menstrual cycle.
Piora de crises epilépticas durante o período menstrual em mulheres com epilepsia focal sinto-
mática
RESUMO - I n t rodução: Admite-se que a flutuação hormonal seja a responsável para a piora de crises epilépti-
cas no período catamenial. Objetivo: Identificar irregularidades nos ciclos menstruais de mulheres com
epilepsia de lobo temporal mesial (ELTM) e epilepsia focal extratemporal (EFET); e relacionar a frequencia d e
crises durante o ciclo menstru a l . Método: Avaliamos mulheres na menacme, que apresentem quadro clí-
nico laboratorial compatível com ELTM e EFET. Foram fornecidos calendários para estas pacientes e instru íd a s
para preenchimento correto da menstruação e das crises epilépticas e serão revistos em cada consulta médi-
ca ro t i n e i r a . Resultados: Foram avaliadas 39 pacientes com ELTM e 14 com EFET. Registramos 211 ciclos
nas pacientes com ELTM e 49 nas com EFET. Ciclos menstruais irre g u l a res foram apresentados por 28 (71,7%)
pacientes com ELTM e 14 (42,8%) com EFEP (p=0,052).  Piora pré-menstrual foi observada em 46 (21,8%)
pacientes com ELTM e 9 (18,3%) com EFET (p=0,596). Piora menstrual foi observada em 47 (22,2%) pacientes
com ELTM e 15 (30,6%) com EFET (p=0,217). Piora ovulatória foi observada em 36 (17%) pacientes com E LT M
e 13 (26,5%) com EFET (p=0,126). Piora catamenial foi observada em 58 (27,4%) das pacientes com ELTM e
em 17 (34,7%) das pacientes com EFET (p=0,315). Conclusão: Não houve diferença entre os grupos de pa-
cientes com ELTM e EFET quanto à freqüência de ciclos irre g u l a res e piora das crises nos períodos pré-men-
strual, menstrual, catamenial ou ovulatório.
PA L AV R A S - C H AVE: epilepsia, catamenial, epilepsia de lobo temporal, epilepsia extratemporal, ciclo mens t ru a l .
Epilepsy has an estimated prevalence between
1 and 1.8%1 - 3. The incidence of epilepsy in women
is similar to that in men. Anovulatory cycles are m o-
re frequent in women with epilepsy. In addition,
it seems that epileptic seizures are more fre q u e n t
in anovulatory cycles than in normal cycles4. There
a re re p o rts that up to 50% of women with epilep-
sy in the menacme present worsening of seizures
through the menstrual cycle5.
H e rzog et al.6 described three standards of sei-
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z u re worsening related to diff e rent periods of the
m e n s t rual cycle: a) seizures that occur during the
t h ree days before menses and on the first three days
of menses; b) seizures that occur close to the mid-
dle of the cycle, before the ovulation between the
8t h and 14t h days; c) seizures that are frequent bet-
ween the 8t h day of a cycle and the 2n d day of the
next; these cycles are anovulatory. This last standard
is more difficult to identify, comparing to those that
occur in normal menstrual cycles. Experimental studi-
es showed that estrogen is epileptogenic and pro g e s-
t e rone protects against seizure s7. Epileptiform activi-
ty is observed during menses, on the days that pre c e-
de it and in the middle of the menstrual cycle. Pa-
tients with both partial and generalized epilepsies
p resent catamenial seizure worsening8.
The objective of this study was to identify irre g-
ularities in the menstrual cycles of women with
mesial temporal lobe epilepsy (MTLE) and extra-
temporal focal epilepsy (ETFE), and correlate the
frequency of seizures during menstrual cycle.
METHOD
Women in fertile age were evaluated. Patients were
seen at the epilepsy clinic of our University Hospital.
MTLE was characterized according to clinical end elec-
t roencephalographic criteria established by the ILAE9. Pa-
tients presented seizures with epigastric sensation, nau-
sea, autonomic signs, eructation, pallor, facial flush, activi-
ty break, pupillary dilatation, fear, panic and olfactory a n d
gustative hallucination9. Neuroimaging evaluation by
high resolution showed hippocampal atrophy and hyper-
intense T2 signal indicating mesial temporal sclero s i s .
ETFE was based on clinical, EEG and neuro i m a g i n g
findings of frontal, parietal and occipital epilepsy10,11.
E v e ry patient was submitted to a questionnaire
c o n c e rning gynecological and obstetrical antecedents
and detailed menstrual history. In addition they were
asked to fill out of the calendar re g a rding the menstru-
al period. 
We considered as irregular cycles the ones short e r
than 26 days and longer than 32 days of duration. 
Inclusion criteria – a) Women in the menacme with
MTLE and ETFE diagnosis according to the criteria of
the ILAE for at least one year9 ;b) MRI and EEG investiga-
tion perf o rmed at our institution; c) Good compliance
to the treatment and available telephone for contact if
needed; d) Attendance to clinical follow-ups re g u l a r l y ;
e) Fill out the calendar properly; f) Absence of horm o n-
al therapy or the use of valproate; g) Signature of infor-
med consent submitted and approved by the Research
Ethics Committee of the institution. 
Analysis of the data – The analysis of the data was
based on the diff e rent periods of the menstrual cycle.
The average of crises per day was calculated for each p e-
riod and compared to other days of the cycle.  We estim a-
ted worsening when the average of seizure/day in a de-
termined period of the cycle was higher than the either
average of the other days or twice or three times the
average.
Table 1. Patients with extratemporal focal epilepsy.
N* Age Menarc First Type Epileptiform Normal MRI Drugs in use
(years) (years) seizure EEG EEG
1 40 12 19 years SPS/CPS/GTCS YES NO normal LTG 400mg/CBZ 1000mg
2 35 15 11 years SPS/CPS/GTCS YES YES L sulcus atrophy CBZ 1600mg/CLB 10 mg
3 25 13 4 years CPS YES NO double cortex CBZ 1200mg/VGB 750mg/
TIORAZIDE 50mg
4 20 13 4 years GTCS YES NO bilateral occip gliosis CBZ/TPM/CLN
5 26 14 1y 8month SPS/CPS/GTCS NA NA PNH CLB 10/TOPAMAX 100
RTO cortical
6 32 NA 8 years SPS/CPS/GTCS YES NO displasy PB 300mg/CLB 40mg
7 40 12 9 years SPS YES NO normal CBZ 600mg
8 22 14 6 years SPS/CPS YES NO R frontal gliosis CBZ 600mg/ CLBl 40mg
9 28 14 14 years SPS/CPS/GTCS YES YES LOR dural AVMF CBZ 400mg
10 34 11 4 years SPS/CPS. YES NO neurocisticercosis OXC 2100/CLB 40
11 36 10 9 years SPS/CPS/GTCS YES NO calosotomy CBZ 1200mg/VPA 1500mg/CLB 20
12 30 9 27 years SPS/CPS/GTCS NO YES NA OXC 600mg/PHT 100mg
13 41 12 13 years SPS/CPS/GTCS YES NO CDMF in LFR OXC 1800 mg
14 25 13 7 years CPS YES NO normal CBZ 1200mg/CLB 60 mg/AMT 75mg
SPS, simple partial seizure; CPS, complex partial seizure; GTCS, generalized tonic-clonic seizures; HÁ, hipocampal atrophy; R, right; L, left; NA, not
available; AV M F, arterial-venous malformation; R- region; O- occipital; T- temporal; F-frontal; CDMF, cortical development malformation; Cort , c o r-
tical; PNH, periventricular nodular heterotopy; CBZ, carbamazepine; CLB, clobazam; OXC, oxcarbazepine; LGT, lamotrigine; PHT,phenytoin; VPA ,
valproate; PB, phenobarbital; ETX, etossuximide; TPM, topiramate; CLN, clonazepam; AMT,amitriptiline, MRI, magnetic resonance imaging.
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P re m e n s t rual period: three days before the first day
of the cycle (the menstruation first day).
Menstrual period: period when there was bleeding
until the fifth day.
O v u l a t o ry period: period of 5 days, 14 days before
the menstruation ± 2 days. 
Catamenial period: pre m e n s t rual period + menstru-
al period. 
Catamenial worsening: three-fold increase in seizure
frequency in relation to the other days of the cycle.
Statistical analysis was perf o rmed using the Chi-
Square test.
RESULTS
T h i rty-nine patients with MTLE and 14 with
ETEF were evaluated (Tables 1 and 2). We re g i s t e-
red 211 cycles in patients with MTLE and 49 in tho-
se with ETFE.
I rregular menstrual cycles were presented by
28 (28/39, 71.7%) patients with MTLE and 6 (6/14,
Table 2. Patients with temporal lobe epilepsy.
N* Age Menarc First TypeYPE Epileptiform Normal EEG MRI Drugs in use
(years) (years) seizure EEG
1 47 15 15 years SPS/CPS/GTCS NO YES RHA CBZ 1200mg/CLB 20mg
2 42 15 3 years CPS YES YES LHA CBZ 1200mg/CLB 40mg
3 25 12 14 years SPS/CPS/GTCS YES NO RHA CBZ 600 mg/LGT 200mg/CLB 30mg
4 37 13 13 years SPS/CPS NA NA NA PHT 200mg/ CLB 10 mg
5 36 13 4 years SPS YES NO LHA CBZ 1400mg/CLB 20mg
6 39 13 20 years SPS/CPS/GTCS YES NO LHA CBZ 600mg
7 33 15 18 years SPS/CPS YES NO LHA CBZ 800mg/CLB 20mg
8 39 14 8 years CPS/GTCS YES NO LHA CBZ 800mg/CLB 20mg
9 36 13 2 years CPS/GTCS YES NO LHA CBZ 1200mg/VPA 600mg/LGT
250mg/CLB 20mg
10 22 11 14 years CPS/GTCS YES NO LHA CBZ 600mg
11 24 12 NA SPS/CPS/GTCS YES YES RHA PB 150mg
12 38 18 20 years SPS/CPS/GTCS NO YES normal CBZ 1000mg
13 20 13 15 years SPS/CPS   NO YES LHA CLB 20mg/CBZ1000mg
14 20 12 10 years SPS/CPS/GTCS YES YES LHA CBZ 1200mg
15 43 10 1 year SPS/CPS YES YES RHA OXC 2100 mg/CLB 30mg
16 42 12 2 years CPS/GTCS YES YES RHA CLB 30mg/OXC 600mg
17 37 13 3 years SPS/CPS YES YES RHA CBZ 800mg/CLB 10mg
18 38 13 24 years SPS/CPS/GTCS YES YES RHA PB 250 mg/CLB 20mg
19 48 12 26 years SPS/CPS/GTCS YES NO NA CBZ 600mg
20 42 14 7 years SPS/CPS/GTCS YES YES LHA CBZ 600mg
21 30 10 11 years SPS/CPS/GTCS NO YES LHA CBZ 1300mg/CLB 40mg
22 42 14 18 years SPS YES NO NA ETX 750mg
23 30 12 4 years CPS/CPS/GTCS YES NO NA CBZ 1100mg/CLB 20mg
24 33 13 1 year SPS/CPS/GTCS YES YES RHA CBZ 1200mg/CLB 30mg
25 46 13 15 years CPS YES YES LHA CBZ 1000mg/CLB 20mg
26 17 10 7 years CPS/GTCS YES NO LHA CLB 20mg/ CBZ 1200mg
27 39 12 11 years CPS YES NO RHA CBZ1200mg
28 40 10 2 years SPS/CPS/GTCS YES NO RHA CBZ 1200mg/CLB 10mg
29 33 11 25 years SPS/CPS/GTCS YES YES RHA CBZ 800mg
30 28 14 1 year CPS YES NO LHA CBZ  1000mg
31 36 13 13 years SPS/CPS YES YES RHA CBZ 1000mg/CLB 10 mg
32 38 11 14 years CPS YES NO cerebellar atrophy CLB 40mg/CBZ 900mg/
NORTRIPTILINE 60mg
33 28 12 7 years SPS/CPS/GTCS YES NO RHA CBZ 1200mg/ CLB 40mg
34 34 14 28 years SPS/CPS/GTCS YES NO normal OXC 600mg/CLB 20mg
35 30 12 4 years SPS/GTCS YES YES LHA, neurocisticercosis CBZ 800mg/CLB 10 mg
36 40 14 3 years SPS/CPS/GTCS YES NO RHA CBZ 1200mg
37 42 15 11 mounths CPS/GTCS YES NO RHA CBZ 1200mg
38 22 11 16 years SPS/CPS/GTCS NO YES Normal CBZ 400mg/CLB 10mg
39 35 12 4 years SPS/CPS/GTCS YES NO BilateralHA CBZ 400mg/VPA 2000mg
SPS, simple partial seizure; CPS, complex partial seizure; GTCS, generalized tonic-clonic seizures; HA, hipocampal atrophy; R, right; L, left; NA, not
available; AV M F, arterial-venous malformation; CBZ, carbamazepine; CLB, clobazam; OXC, oxcarbazepine; LGT, lamotrigine; PHT,phenytoin; VPA, val-
proate; PB, phenobarbital; TPM, topiramate; CLN, clonazepam; MRI, magnetic resonance imaging.
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42.8%) with ETFE (p= 0.052). Information related
to seizure counting and regular and irregular men-
s t rual cycles are in Table 3 and 4. Menstrual worse-
ning was observed in 46 cycles (21.8%) of patients
with MTLE and 9 cycles (18.3%) of patients with
ETFE (p= 0.596). Menstrual worsening was obser-
ved in 47 cycles (22.2%) of patients with MTLE and
15 cycles (30.6%) of patients with ETFE (p= 0.217).
O v u l a t o ry worsening was observed in 36 cycles
(17%) of patients with MTLE and 13 cycles (26.5%)
of patients with ETFE (p= 0.126). 
Catamenial increasing of seizures (seizures pre-
dominantly on the pre and menstrual cycles) was
o b s e rved in 58 cycles (27.4%) of patients with
MTLE and in 17 cycles (34.7%) of patients with E T F E
(p=0.315). Catamenial worsening (according to our
definition of three-fold increase in seizure fre q u e n-
cy in relation to the other days of the cycle) was p re-
sent in 29 (13.7%) of the patients with MTLE and
4 (8.1%) of the patients with ETFE (p= 0.290)
DISCUSSION
Catamenial epilepsy refers to seizures re l a t e d
to menstrual cycle and affects approximately m
10-70% of women with epilepsy, depending on
the definition of worsening6. Experimental studi-
es demonstrated that the ovarian steroid hormo-
nes affect the neuronal excitability, that way they
give support to a biologic base for these fluctua-
tions in epilepsy that occur in association with the
m e n s t ruation, from the menarche to the meno-
p a u s e1 2 - 1 9. The low levels of pro g e s t e rone in the
menses, the rising of estrogen level in the ovula-
tion and low levels of pro g e s t e rone during the lu-
teal phase of anovulatory cycles are among the se-
veral factors that precipitate the catamenial epilep-
s y. These factors result in the elevation of the estro-
g e n / p ro g e s t e rone ratio2 0. A decrease on serum lev-
els of the antiepileptic drugs on the days that pre-
cede the menstruation, can also contribute for the
p re m e n s t rual exacerbation of the seizures. It is
supposed that the lower serum levels of antiepilep-
tic drugs is due to an increase in their metabolism
by the hepatic microsomal enzyme system that in-
volves the gonadal steroid metabolism19.
Mattson et al.4 re p o rted an increase in seizure
f requency during the anovulatory cycle, mainly
during the estrogen peak. Jansen and Va e rn e t2 1
related larger incidence of amenorrhea in women
with MTLE than in the general population of wo-
men. Our data showed that one third of patients
evaluated presented catamenial seizure worsen-
ing; if we accept the definition proposed by  Her-
zog et al.6 - higher frequency of seizure on the ca-
tamenial (pre + menstrual) period than that of the
rest of the cycle. 
We evaluated the menstrual disorders in pa-
tients with MTLE and ETFE because of the fact that
these conditions are well-defined electro-clinic syn-
d ro m e s1 0 , 1 1 , 2 2 , 2 3. These two forms of lesional epilep-
sies, frequently re f r a c t o ry to the antiepileptic dru g
(AED) treatment, were evaluated in women who
did not use hormone therapy or sodium valpro a t e .
It is confirmed that the use of valproate incre a s e s
the occurrence of anovulatory cycles, mainly in w o-
Table 3. Presence of regular and irregular menstrual cycles, and re g i s t e red seizures in
patients with ETFE.
Identification # of registered # of registered regular cycle irregular cycle
cycles seizures 26-32 days <26 ou >32days
1 2 21 1 1
2 1 0 0 1
3 8 114 4 4
4 4 71 3 1
5 5 2 5 0
6 1 7 1 0
7 2 17 2 0
8 2 282 2 0
9 5 0 5 0
10 2 404 2 0
11 4 83 3 1
12 2 7 2 0
13 5 0 5 0
14 6 26 3 3
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men with generalized idiopathic epilepsy2 4 , 2 5. Theo-
re t i c a l l y, the group of patients with limbic lesions
(MTLE) would be more inclined to hormonal dys-
functions originated from the influence of limbic
s t ru c t u res on the hypothalamus and hypophysis
and the consequent hormonal disorder and pos-
sible influence on the menstrual cycle. 
A n o v u l a t o ry cycles occur in 14 to 39% on the
diverse forms of epilepsy in women2 6 , 2 7. Accord i n g
to the methodology utilized, we did not evaluate
the patients under the endocrinologic point of view
(if the irregular cycles observed were anovulatory
or not). Nevertheless, it is known that 11% of wo-
men with epilepsy have cycles with intervals out of
the period of 21-35 days, which is larger than what
is expected on the general population, about
2 %2 6 , 2 8 , 2 9. We adopted the period of 26-32 days for
the definition of regular cycles based on the Herz o g
and Friedman’s findings2 6, who found significant
increase  of anovulatory cycles out of this period. It
Table 4 - Presence of regular and irregular menstrual cycles, and registeredseizures in
patients with MTLE.
Identification #of registered #of registered regular cycle irregular cycles
cycles seizures 26-32 days <26 ou >32days
1 5 5 2 3
2 6 13 1 5
3 4 86 2 2
4 7 25 3 4
5 3 0 3 0
6 4 10 4 0
7 19 132 13 6
8 6 41 6 0
9 6 20 3 3
10 2 0 2 0
11 17 52 1 16
12 2 0 1 1
13 13 3 3 3
14 4 94 3 1
15 11 11 6 5
16 6 20 3 3
17 6 30 5 1
18 1 0 0 1
19 3 9 3 0
20 5 6 2 3
21 5 0 5 0
22 2 166 1 1
23 2 10 2 0
24 2 10 1 1
25 7 13 3 4
26 3 50 3 0
27 2 12 0 2
28 3 0 2 1
29 10 1 8 2
30 5 4 5 0
31 5 13 5 0
32 3 30 2 1
33 3 0 2 1
34 12 46 11 1
35 5 7 2 3
36 9 212 5 4
37 5 36 3 2
38 2 2 2 0
39 3 11 1 2
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is known that the irregular cycles have higher pro b-
ability of being anovulatory2 6. The irregular cycle
finding has clinic importance because the fre q u e n-
cy of epileptic seizures is higher in these cycles6 , 2 0.
In addition, the incidence of re p roductive endocrine
d i s o rders is higher in these women3 0 - 3 2, part i c u l a r-
ly the polycystic ovary syndro m e3 2 - 3 4. These distur-
bances are associated with an increase of the infert i-
lity rate, migraine, emotional disturbances, re s i s t a n-
ce to insulin, cardiovascular disease and cancer3 5.
The real role of the irregular or anovulatory cycles
in these patients and their medical dimension need
c o m p l e m e n t a ry investigations. 
A recent study about long-term re p ro d u c t i v e
endocrine health in young women with epilepsy
during puberty have shown that 56% patients tak-
ing antiepileptic medication, 32% of patients with-
out drugs and 38% normal control presented irre g-
ular menstrual cycles. They defined irregular cycle
if the interm e n s t rual variation was > 7 days or the
cycle duration was >35 days or <21 days, at least
once during the preceding 6 months. In the same
s t u d y, Mikkonen et al.3 6 found that polycystic ovary
s y n d rome was more common in patients on medi-
cation (38%, mainly valproate) than in patients w i t h-
out medication (6%) or in controls (11%). These a u-
t h o r s3 6 p roposed that irregular menses may be con-
s i d e red an adverse event of antiepileptic drug t re a t-
ment, particularly in puberty. 
T h e re was no seizure worsening diff e rence on
the pre m e n s t rual, menstrual, catamenial or ovula-
t o ry periods in the two groups of patients we stud-
ied. This is a pre l i m i n a ry study and a larger sam-
ple should be evaluated in order to confirm our
findings. 
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